PARP1 and amyotrophic lateral sclerosis: Evidence from tissue culture and C. elegans models support NEDP1 as a therapeutic target for ALS through the elimination of aberrant aggregates, and mechanistic work highlights its regulation of PARP1 as particularly significant (Figure 3) [112,119,121].